Conversion from Immediate-Release to Extended-Release Venlafaxine
When converting from immediate-release (IR) to extended-release (XR) venlafaxine, use the same total daily dose but administer it once daily instead of divided doses. This is a straightforward 1:1 conversion based on the FDA labeling and pharmacokinetic data 1.
Conversion Table
| Immediate-Release (IR) Dose | Extended-Release (XR) Dose | Dosing Frequency Change |
|---|---|---|
| 37.5 mg twice daily (75 mg/day total) | 75 mg once daily | BID → QD |
| 75 mg twice daily (150 mg/day total) | 150 mg once daily | BID → QD |
| 112.5 mg/day (divided doses) | 112.5 mg once daily | Multiple → QD |
| 225 mg/day (divided doses) | 225 mg once daily | Multiple → QD |
Key Conversion Principles
The total daily dose remains unchanged during conversion. The FDA labeling explicitly states that venlafaxine is available in both "short- and long-acting preparations" and that efficacy has been demonstrated with both formulations at equivalent total daily doses 1.
Practical Conversion Steps:
- Calculate the current total daily IR dose (add all doses taken throughout the day)
- Switch to the same total daily dose of XR formulation given once daily
- Administer XR in the morning for optimal tolerability
- Make the switch directly - no tapering or overlap period is needed when converting between formulations
Pharmacokinetic Rationale
The XR formulation differs from IR in several important ways that support once-daily dosing 2, 3:
- Lower peak plasma concentrations (Cmax) - reduces acute side effects
- Delayed time to peak (higher Tmax) - smoother drug delivery
- Longer apparent elimination half-life - maintains therapeutic levels over 24 hours
- Reduced nausea and dizziness at treatment initiation compared to IR 2, 3
Research demonstrates that XR 75-150 mg once daily was significantly more effective than IR 75-150 mg/day (divided doses) in reducing depression rating scales, despite equivalent total daily doses 3. This suggests the XR formulation may offer clinical advantages beyond convenience.
Clinical Considerations
Monitor for the first 1-2 weeks after conversion. While the conversion is generally well-tolerated, the XR formulation's pharmacokinetic profile means patients may experience:
- Less nausea during the first 2 weeks compared to their initial IR experience 3
- Improved compliance due to once-daily dosing 2
- Potentially better efficacy at equivalent doses 4, 3
Do not crush, chew, or dissolve XR capsules - this destroys the extended-release mechanism and converts it back to immediate-release kinetics.
For patients on higher doses (>225 mg/day), the same 1:1 conversion applies up to the maximum dose of 375 mg/day 1.
Special Populations
The conversion ratio remains 1:1, but dose adjustments may be needed based on organ function 1:
- Hepatic impairment: Reduce total daily dose by 50% (applies to both formulations)
- Renal impairment (GFR 10-70): Reduce total daily dose by 25%
- Hemodialysis: Reduce total daily dose by 50%
- Elderly patients: No dose adjustment needed based on age alone, but titrate cautiously